Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.51 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16329967 | 0.97 | TDP1 (0.51) | TDP1FOLH1PLCD1PRSS1PRSS2 | |
| SCHEMBL16329968 | 0.95 | TDP1 (0.49) | TDP1FOLH1PLCD1PRSS1PRSS2 | |
| SCHEMBL13045429 | 0.95 | TDP1 (0.49) | TDP1FOLH1PLCD1PRSS1PRSS2 | |
| SCHEMBL16330041 | 0.94 | TDP1 (0.57) | TDP1FOLH1PLCD1PRSS1PRSS2 | |
| SCHEMBL14524594 | 0.92 | TDP1 (0.43) | TDP1FOLH1PLCD1PRSS1PRSS2 | |
| SCHEMBL13045423 | 0.92 | TDP1 (0.47) | TDP1FOLH1PLCD1PRSS1PRSS2 | |
| SCHEMBL16350682 | 0.89 | FOLH1 (0.51) | TDP1FOLH1PLCD1PRSS1PRSS2 | |
| SCHEMBL12387575 | 0.89 | TDP1 (0.40) | TDP1FOLH1PLCD1PRSS1PRSS2 | |
| SCHEMBL16299318 | 0.88 | TDP1 (0.48) | TDP1FOLH1PLCD1PRSS1PRSS2 | |
| SCHEMBL10085177 | 0.88 | PRSS1 (0.41) | TDP1FOLH1PLCD1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189692-A1 | ASSAY FOR PATHOGENIC CONFORMERS | NOVARTIS AG | 2011-08-04 | — | — | US | disclosed |
| US-20070087972-A1 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087972-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | TDP1 1545/4885FOLH1 416/4885PLCD1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.